Search

Glubran2 is a cyanoacrylate-based synthetic glue modified by addition of a second monomer. Among its many advantages over traditional cyanoacrylate products, Glubran2 has a much lower thermal polymerization temperature than that of cyanoacrylates used for cutaneous application. For many years, the new glue has been widely used in neuroradiology endovascular treatments. Our study aimed to assess the use of Glubran2 to treat possible complications arising during the embolization of aneurysms or vascular malformations like AVM or fistulae. A complication encountered in some of these cases is rupture of the vessel wall by the microguide or perforation of the aneurysmal sac by the coils used for embolization. This complication could be overcome by injecting Glubran2 into the rupture point but this would put the glue directly in contact with the subarachnoid space and possibly reach adjacent brain tissue. The aim of this experimental study was to place the glue in direct contact with brain tissue to ascertain its immediate compatibility and tolerability in vivo and any ensuing tissue damage. Three swine underwent neurosurgical procedures and survived for different times after which they were slaughtered and their brains explanted and sent for macroscopic and microscopic investigation by the Pathological Anatomy Service. As a whole, Glubran2 was well tolerated in vivo and did not cause major damage in direct contact with brain tissue.

Without Abstract:

The use of microbial additives in rations has become a common practice in ruminant’s nutrition. The main purpose on their use is to increase cattle performance and production from early stages. Their active principle is unclear, but some of their compounds are known to have an effect over performance and gut health. One of these additives are yeast cultures like Saccharomyces cerevisiae fermentation products (SCFP). The objectives of this study were to evaluate the effect of SCFP on growth, DMI, and plasma glucose and NEFA concentration in bottle fed calves. Eighty newborn heifers (n=40 per treatment), block by birth day, were involved in the experiment. Immediately after they were born they were randomly assigned to a control (C) treatment or SCFP supplemented treatment. Calves in C received 2 L of colostrum at birth, 12 and 24 hours after birth and 3 L of milk twice a day. They were offered ad-libitum access to a solid concentrate since day 3. Calves on SPFC received similar feeding but 1 g of SCFP (Smart Care) was added daily on the colostrum or milk in the morning feeding, and 0.7% of SCFP (NutriTek) was added to the solid feed. Body weight (BW, kg) was recorded at birth and on days 14 and 30. Dry feed offered was measured daily and refusals were measured twice a week for 2 weeks. Data was combined to obtain a weekly average daily DMI. Blood was sampled on days 7 and 14 to evaluate plasma glucose and NEFA concentration. Data was analyzed as a randomized complete block design with repeated measurements (SAS 9.4). The model included the random effect of birth day (block), and the fixed effect of treatment, time and the interaction of treatment by time. There was no effect on BW (P=0.20), DMI (P>0.6) nor plasma glucose concentration (P=0.63) but there was a time by treatment effect on plasma NEFA concentration (P=0.04) in which C had a plasma NEFA concentration of 267.1 and 206.6 ± 15.58 µM for day 7 and 14 and SCFP had a 238.3 and 235.1 ± 14.55µM for day 7 and 14, respectively. Therefore, feeding SCFP might contribute in a lower fat mobilization when compared with C during the first week of life, possible due to a reduction on an energetic challenge on a healthier gut. However, more research needs to be done to address this specific area of study.